ClinicalTrials.gg
RecruitingNCT07207564Updated Aug 27, 2026

Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk

An observational study in Breast Carcinoma, sponsored by Mayo Clinic. Recruiting at 2 sites in United States. Open to female participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Mayo Clinic · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,500
Ages
18 Years to 100 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 160 studies in Breast Neoplasms by Mayo Clinic — 30 open to participants now, 41 under way, 1 of them phase 3. Breast Neoplasms · Mayo Clinic.

Planned enrollment
Largest of 62
4,500 · median 95
Started
2025
with 11 others
Observational
62 of 160
9 open now
Primary completion
2030-06
later than 32 of 40 live
Registered
154th of 160
by date

Among the 160 studies in Breast Neoplasms by Mayo Clinic, this one has the largest planned enrollment of the 62 observational ones that give a count, is one of 12 that started in 2025, is one of 62 observational ones, reaches primary completion later than 32 of the 40 other live ones, and was the 154th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

30 of the 160 studies in Breast Neoplasms by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 100 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Breast Neoplasms by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this research is to better understand how benign breast diseases might lead to breast cancer, focusing on genetic factors and including a diverse range of participants to improve future diagnosis and treatment.

03

Conditions studied

  • Breast Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Women who had a benign breast biopsy at Mayo Clinic between 2002 and 2022.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients, ages 18 to 100 years
  • Had a benign breast at Mayo Clinic between 2002-2022

Exclusion criteria

Exclusion Criteria:

  • All male patients
  • Prior or concomitant diagnosis of BC
  • Diagnosis of BC within six months of benign breast disease
  • Denial of research authorization
  • Concurrent or post- bilateral prophylactic mastectomy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,500 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Observational

    Participants complete a questionnaire, undergo collection of saliva or blood samples, and have their medical records reviewed on study.

    Other: Non-Interventional Study

Interventions

  • OtherNon-Interventional Study

    Non-interventional study

    Also known as: Non-Interventional Observational Study, Noninterventional (Observational) Study

06

What researchers measure

Primary outcomes

  1. Pathologic features

    Will examine pathologic features from benign tissue to define features related to breast cancer (BC) risk.

    Time frame: Baseline (collection of blood or saliva sample)

  2. Radiologic features

    Will examine radiologic features from mammographic images at time of benign breast disease (BBD) to define features in mammogram images that predict BC risk among women who have a history of BBD. We will also assess whether these features predict BC risk among women without a history of BBD.

    Time frame: Baseline (collection of blood or saliva sample)

  3. Molecular features

    Will examine molecular features to understand how molecular features, including DNA damage and repair work in the breast tissues of women with BBD and how this might relate to risk of developing BC

    Time frame: Baseline (collection of blood or saliva sample)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2030, 58 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 58 months is close to that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Oct 6, 2025
StartActual
Aug 28, 2025
Primary completionEst.
Jun 30, 2030
CompletionEst.
Jun 30, 2030
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07207564
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
Aug 28, 2025
Primary completion
Jun 30, 2030 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Aug 27, 2026

Study contacts

Laura Pacheco-Spann
Contact
pachecospann.laura@mayo.edu
904-953-0408
Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
Mark E. Sherman, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion